Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurological and Autoimmune Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for KCNA2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KCNA2 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed for native glycosylation. |
View KCNA2 Products |
| Gene Delivery | KCNA2 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction. Ideal for preserving native tetrameric ion channel conformation. |
View KCNA2 Products |
| Benchmark Ab | Anti-KCNA2 Recombinant Antibody Recombinant positive control sequence verified for binding assays. |
View KCNA2 Products |
| Validator | KCNA2 siRNA Set For target knockdown and specificity verification in cell-based assays. |
View KCNA2 Products |
| Related Target A | KCNA1 (Kv1.1) Critical homolog for selectivity and counter-screening to avoid off-target neurotoxicity. |
View KCNA1 Products |
| Related Target B | KCNA3 (Kv1.3) Homologous channel involved in immune cell activation; essential for selectivity profiling. |
View KCNA3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Preservation of Multi-pass Membrane Proteins | Lentivirus-mediated stable cell line generation preserves native tetrameric structures for patch clamp and flux assays. |
| Subfamily Selectivity Counter-Screening | Sequence-verified KCNA1, KCNA2, and KCNA3 panels available for high-throughput selectivity profiling. |
| Lack of Validated Positive Controls | Sequence-verified recombinant benchmark antibodies included for assay standardization. |
| False Positive Knockdown Signals | Multi-sequence validated siRNA pools included for highly specific knockdown verification. |
Live KCNA2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the voltage-gated potassium channel KCNA2 (Kv1.2) is rapidly evolving. Historically viewed as a challenging ion channel target due to high sequence homology across the Kv1 family, drug discovery is transitioning from non-selective small-molecule channel blockers to highly selective modulators, peptide toxins, and antibody-based therapeutics. As clinical understanding of KCNA2-related channelopathies (such as epileptic encephalopathy and cerebellar ataxia) deepens, the next wave of R&D focuses on state-dependent modulators that selectively target open, closed, or inactivated channel states without cross-reacting with cardiac-related channels like Kv1.5 or hERG.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PAMs/NAMs) | Xenon Pharmaceuticals, Neurocrine Biosciences | Epileptic Encephalopathy, Ataxia | Electrophysiology Validation (Need Lentivirus for stable cell line expression) |
| Peptide Toxins (Venom-derived) | Kineta, Alomone Labs (Research) | Neuropathic Pain, Autoimmune Diseases | Selectivity Screening (Need KCNA1/KCNA2/KCNA3 recombinant panels) |
| Monoclonal Antibodies | Amgen, Target-specific biotechs | Central Nervous System Disorders | Conformational Binding (Need HEK293-expressed extracellular loop fragments) |